WuXi PharmaTech ($WX) won Clinical Laboratory Improvement Amendments (CLIA) certification for its Shanghai genomics lab, making it the first such outfit in China to meet U.S. testing standards. With the approval, WuXi is now clear to undertake various clinical trial gene sequencing projects to support U.S.-based development efforts. News